Korsana Biosciences, Inc.

Korsana Biosciences, Inc. is a biotechnology company focused on developing innovative therapeutics for serious neuropsychiatric disorders with significant unmet medical needs. The company's primary strategic focus is on a novel therapeutic approach for neuropsychiatric conditions, with its lead indication being treatment-resistant depression ("TRD"). Korsana Biosciences, Inc. refines its strategic direction towards programs that combine established pharmacologic agents with enabling technologies to improve precision, reproducibility, and patient outcomes. As part of this strategy, the company has prioritized CYC-126, an individualized therapy for TRD, as its foundational development program. In September 2025, Korsana Biosciences, Inc. entered into a license agreement with the Massachusetts Institute of Technology ("MIT") for intellectual property supporting this program. Under this agreement, MIT is eligible to receive up to $4.4 million upon the achievement of certain development, regulatory, and sales milestone payments. MIT will also receive tiered royalties in a range of percentages in the low single digits based on future net sales of licensed products, and varying percentages of income from any sublicenses granted. In January 2026, the company entered into a collaboration and option-to-license agreement with Medsteer SAS ("Medsteer") to access technology, data assets, and technical know-how related to drug delivery and physiological monitoring. Under this agreement, Korsana Biosciences, Inc. will pay Medsteer a nominal upfront payment, a payment upon exercise of the Option, and Medsteer is eligible to receive up to $3.7 million upon the achievement of certain development, regulatory, and sales milestone payments. Medsteer will also receive an annual royalty payment and royalties in a percentage in the low single digits based on future net sales of licensed products.